CNS Amyloid- , Soluble APP- and - Kinetics during BACE Inhibition
Randall J. Bateman(Washington University in St. Louis), Kristin R. Wildsmith(Genentech), Bruce W. Patterson(Washington University in St. Louis), Parker D. Mathers(Center for Agricultural Resources Research), Declan M. McLoughlin(Psychiatry Research Trust), David B. Gilberto(Center for Agricultural Resources Research), Daniel Holder(University of California San Diego), Matthew Kennedy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kevin E. Yarasheski(Washington University in St. Louis), Maria S. Michener(United States Military Academy), Yuriy Pyatkivskyy, A. W. STAMFORD(Institute of Medicinal Plant Development), Robert Chott(Washington University in St. Louis), Christina Lennox(Center for Agricultural Resources Research), Guoxin Wu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mary J. Savage(Brandywine Photonics (United States)), Thomas P. Kasten(Northwestern University), Vladimir Ovod, Mandy Dancho(Center for Agricultural Resources Research), Benn E. Smith(Center for Agricultural Resources Research)
Cited by 40
Related Papers
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
|New England Journal of Medicine|1997|1.9k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2017|1.3k
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease
|Nature Medicine|2019|948
Selective inhibition of the inducible nitric oxide synthase by aminoguanidine
|European Journal of Pharmacology|1993|727